Skip to main
XTNT

XTNT Stock Forecast & Price Target

XTNT Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Xtant Medical Holdings is a medical technology company that has a clear growth strategy in place to become a leading player in the global orthobiologics market. With a focus on spinal implants and orthobiologics products, along with a network of independent distributors and stocking agents, the company is well positioned to capitalize on the ongoing consolidation in the spine market and the strong demand for its products. Additionally, with a strong capital position and a history of bringing in new assets and achieving profitable growth, Xtant has a solid track record for delivering value to investors.

Bears say

Xtant Medical Holdings is at a disadvantage compared to its peers in the musculoskeletal MedTech industry due to its relatively low revenue and profitability profile, as well as the risks associated with its orthobiologics business. The company is working to improve its capital position by reducing debt and increasing its cash balance, but its recent acquisition of Dilon Technologies may not provide significant revenue growth in the long term. With shares trading at an attractive valuation, there may be limited downside but the company will need to execute well on product launches and increasing distributor interest to drive share prices higher.

XTNT has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xtant Medical Holdings (XTNT) Forecast

Analysts have given XTNT a Strong Buy based on their latest research and market trends.

According to 2 analysts, XTNT has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xtant Medical Holdings (XTNT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.